Launch of Bosutinib Tablets 400mg - Dr Reddys Laboratories Ltd

Code BSE: 500124 NSE: $DRREDDY Dr. Reddy’s announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States. Milan Kalawadia, CEO- North America, Dr. Reddy’s Laboratories, Inc. said: “This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.”